Floatz logo

Chimeric Antigen Receptor Modified T Cells Infusion

Acute Lymphoblastic Leukemia

King Faisal Specialist Hospital & Research CenterCell therapyPhase 2Active
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
65/ 100

Competitive context

182 Active assets in the Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
THIOGUANINE ANHYDROUS
St. Jude Children's Research Hospital
Phase 4BBB
ASPARAGINASE
Centre Hospitalier Universitaire de Nice
Phase 4BB
MERCAPTOPURINE ANHYDROUS
Dana-Farber Cancer Institute
Phase 4BB
VINCRISTINE SULFATE
Children's Oncology Group
Phase 3BB
PEGASPARGASE
Dana-Farber Cancer Institute
Phase 4BB

View all 50 →

Same molecule, other indications

Chimeric Antigen Receptor Modified T Cells Infusion is also rated in:

B Cell LymphomaDormant
BB
Indicative ·
71 / 100
View asset →
Non Hodgkin LymphomaDormant
BB
Indicative ·
67 / 100
View asset →
B-cell Acute Lymphoblastic LeukemiaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →